On November 4th(EST), the first patient was enrolled in IgA nephropathy PhaseⅡclinical trial using Telitacicept in the U.S., the drug was created and developed by RemeGen (荣昌生物-B:09995.HK).


It is a global milestone of Telitacicept IgA nephropathy indication. On December 19th, 2020, IgA nephropathy indication of Telitacicept was granted approval by FDA to enter phaseⅡclinical trial. On August 10th, a Telitacicept phase II IgAtrial in China met its primary endpoint.


At present, there are no novel biologics approved for IgA nephropathy around the world. There are several biologics in clinical trials at various stages in the United States for IgA nephropathy. In China, the number of novel biologics for the treatment of IgA nephropathy is very few in the pipeline, and only Telitacicept has completed phase Ⅱ clinical trial in IgA nephropathy indication.



On November 4th(EST), Telitacicept was presented as Late-Breaking poster at the Annual meeting of the American Society of Nephrology, which is the world's largest and highest level of nephrology academic event.